SPY414.92-5.67 -1.35%
DIA332.96-5.20 -1.54%
IXIC14,030.38-130.97 -0.92%

ALX Oncology Doses First Patient in Phase 2 Study of ALX148 in Combination With Merck's KEYTRUDA

05/10/2021 06:11

09:59 AM EDT, 05/10/2021 (MT Newswires) -- ALX Oncology Holdings Inc (ALXO) said that the first patient has been dosed in a phase 2 study evaluating the combination of its ALX148 with Merck's (MRK) KEYTRUDA to treat patients with advanced head and neck squamous cell carcinoma.

The study will evaluate the anti-tumor efficacy of ALX148 plus KEYTRUDA, and is based on clinical data from a phase 1 study, which was the basis of ALX148's fast-tack designation granted by the US Food and Drug Administration.

Shares of ALX Oncology were down 4% in early Monday trading. Merck's stock was fractionally higher.

Price: 62.39, Change: -2.59, Percent Change: -3.99